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Letter: Troponin T elevation in amyotrophic lateral 
sclerosis without cardiac damage 
 
Running title: Troponin T in ALS without cardiac damage 
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A 65-year old man presented in May 2010 with progressive weakness of arms over the 
course of several weeks, dysarthria and signs of upper and lower motoneuron dysfunction 
with atrophic tetraparesis, fasciculations, spasticity, and hyperreflexia. After exclusion of 
other differential diagnoses by extensive evaluations, clinically definite ALS was confirmed 
(1). ALS functional rating was 29 of 48 points. Riluzole treatment was started. In September 5 
2011, the patient was admitted with acute chest discomfort and nocturnal dyspnoea. Acute 
pulmonary embolism, pneumothorax and other abnormalities were ruled out by contrast-
enhanced computed tomography. An electrocardiogram was normal. The patient was 
discharged after 12 hours observation and resolution of symptoms. Two weeks later, he 
presented with nocturnal dyspnoea and epigastric discomfort. Cardiac markers were slightly 10 
elevated (Table), raising the possibility of acute coronary syndrome (ACS). N-terminal 
prohormone of brain natriuretic peptide, plasma creatinine, arterial blood gases and 
electrocardiogram were normal. Single-photon emission computed tomography (SPECT) with 
adenosine stimulation revealed a normal cardiac contraction and no evidence of ischemia or 
scarring. Over the course of 2 days, no changes in the cardiac troponin T (cTnT) levels were 15 
noted. Spirometry was normal. A sleep study suggested borderline sleep-related alveolar 
hypoventilation and mild central sleep apnoea. Nocturnal positive airway pressure ventilation 
was initiated and pantoprazole (40 mg/d) started for presumed gastritis. He continued the 
nocturnal ventilation at home. Laboratory tests were repeated after 2 weeks (Table). It was 
concluded that the most likely causes of the dyspnea and epigastric discomfort were sleep-20 
related breathing disturbances and gastritis. The initial suspicion of myocardial injury was 
rejected. 
According to international guidelines, diagnosis of ACS relies on electrocardiogram 
and repeated measurements of cTn (2), but the case described here underlines the importance 
of considering differential diagnoses other than ACS as causes of elevated markers of 25 
myocardial necrosis. A moderate creatine kinase (CK) elevation (up to 1000 U/l) is common 
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in ALS patients and may reflect neurogenic muscle atrophy (3). Raised levels of CK-MB and 
myoglobin may origin from various non-cardiac sources. In contrast, the specificity and 
sensitivity of cTnT for cardiac muscle injury is much higher, and its sensitivity increased in 
particular with novel high-sensitivity assays (4). A few rare circumstances with elevated cTn 
of non-cardiac origin have been described (5), but could be excluded in the described ALS 5 
patient. Interfering antibodies that could lead to falsely high cTn levels (6) were unlikely, 
since incubation of the patient’s plasma with a heterophilic blocking reagent left the cTn 
concentration unchanged (Table). Diluting his sample in cTnT-free plasma demonstrated an 
ideal dilution curve (not shown), corroborating the absence of interfering antibodies. Recently, 
an ALS patient with chronically elevated levels of cTnT and cardiac troponin I (cTnI) was 10 
described (7). He had very advanced disease with chronic hypoventilation, and the authors 
ascribed the elevation of cTnT to myocardial hypoxia. Hypoxemia is an unlikely explanation 
of the isolated cTnT elevation without associated cTnI elevation in the current patient, since 
his daytime blood gases were normal and nocturnal oxygen saturation rarely dropped below 
90%. Cases of cTnT without cTnI elevation have been reported (8), although the origin 15 
remained speculative. A potential mechanism is the expression of cTn isoforms in non-
cardiac cells, as observed in muscle biopsies from patients with skeletal muscle myopathies 
(9). Although the ALS patient presented here did not suffer from a myopathy, similar atypical 
cTn expression in other, unexpected cell types may have occurred. However, the cause of his 
laboratory anomalies remained unclear. 20 
We report the first case of an ALS patient in whom respiratory failure could not 
explain the cTnT elevation and several other causes of cTnT elevations had been specifically 
ruled out. In ALS patients presenting with symptoms of ACS, cTn should be measured at 
defined time intervals to capture the rise and/or fall of cTn which is highly suggestive of ACS 
(10). Non-dynamic elevations of cTn may derive from causes other than myocardial damage. 25 
Most importantly, laboratory data should be interpreted in view of patient history, clinical 
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presentation and electrocardiogram before further invasive and costly examinations are 
performed.  
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Table. Laboratory and clinical examinations 
Plasma measurements of cardiac markers 
 Ref Sample 1, 
on admission 
Sample 2,  2 weeks later 
Untreated treated 
with HBT 
NT-proBNP (ng/l) < 376 81 n.d. 43 
Myoglobin (µg/l) 28 - 72 131 118 113 
CK (U/l) < 190 445 338 338 
CK-MB (U/l) 
CK-MB/CK ratio (%) 
< 24 
<6.0 
33 
7.4 
26 
7.7 
27 
8.0 
cTnT (µg/l) < 0.014 0.103 0.166 0.166 
cTnI (µg/l) < 0.040 n.d. < 0.040 < 0.040 
Arterial blood gas analysis spontaneously breathing room air on admission 
pH 7.35-7.45 7.473   
PaCO2 (kPa) 4.5-6.0 3.98   
PaO2 (kPa) >10.0 13.1   
Bicarbonate (mmol/l) 22-26 23.9   
Pulmonary function on admission 
FVC (L, % pred) 4.31 4.27 (99%)   
FEV1 (L, % pred) 3.34 3.05 (91%)   
Sniff nasal pressure, mbar 85 64   
Sleep study during first night after admission 
Mean nocturnal oxygen saturation (%) 
 Oxygen saturation <90% (% TIB) 
>90 
0 
94 
1 
  
Apnea/hypopnea index (events/h) <5 15/h   
Nocturnal rise in PtcCO2 (mmHg) <10 9   
NT-proBNP = N-terminal prohormone of brain natriuretic peptide; CK = creatine kinase, CK-
MB = creatine kinase MB isoform; cTnT = cardiac troponin T by high-sensitivity immuno-
assay, Roche Diagnostics, Switzerland (4th-generation assay: 99th percentile of 0.014 µg/l, 
coefficient of variation ≤ 10% at this concentration); cTnI = cardiac troponin I by automated 
immunoassay, AccuTnI, Beckman Coulter (99th percentile of 0.040 µg/l, coefficient of variation 
of 14% at this concentration); HBT = heterophilic blocking reagent tube, n.d. = not determined; 
FVC, FEV1 = forced vital capacity and expiratory volume in 1 s; PtcCO2=transcutaneous 
PCO2; % TIB= percent of time in bed 
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